Browse articles from EyeWorld.org related to keratoconus. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA issues another response letter for dry eye NDA ➤ FDA denies approval for LHON NDA ➤ Commercial launch of epithelium-on crosslinking in the U.S. ➤ Company news ➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD ➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment ➤ First patient dosed in gene therapy study for optic nerve disorder ➤ Company news
➤ FDA approves epithelium-on crosslinking treatment ➤ 12-month results from Phase 1/2 trial evaluating regenerative cell therapy for corneal endothelial disease ➤ Phase 3 data supports nonsteroidal treatment for uveitic macular edema ➤ FDA approves IDE for glaucoma device ➤ Company news ➤ ASCRS news and events
Two physicians discussed finding the right refraction in patients with keratoconus, what to take into account, and considerations if patients are seeking surgery.
➤ FDA approves first-in-class DED drop ➤ FDA accepts NDA for topical presbyopia therapy ➤ TFOS DEWS III ➤ Topline results in Phase 3 study evaluating night driving impairment after keratorefractive surgery ➤ IND application submitted for pediatric myopia treatment ➤ Study sheds light on clinical inherited retinal diseases without genetic mutations ➤ ASCRS news and events
➤ Voluntary IOL recall ➤ Phase 4 study assesses patient-reported outcomes of dry eye drop ➤ Study: synthetic opsin restores vision in cases of severe retinal degeneration ➤ Phase 3 endpoints not met in trial evaluating wet AMD treatment ➤ Merger news ➤ ASCRS news and events
➤ Study: long-term efficacy of uveoscleral outflow enhancement for glaucoma ➤ FDA grants expanded indication for fluocinolone acetonide intravitreal implant ➤ First patient dosed in Phase 1/2 gene therapy trial targeting Stargardt disease ➤ Merger complete ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Transepithelial crosslinking NDA submission accepted ➤ Fast Track designation granted to drop being investigated for night driving impairment due to visual disturbances ➤ First-in-human interventional study for gene therapy treating Leber congenital amaurosis 4 ➤ Positive outcomes observed for geographic atrophy drug ➤ Regenerative Medicine Advanced Therapy designation granted to stem cell therapy for dry AMD ➤ ASCRS news and events
➤ Topline results for non-steroidal immunomodulator for postop inflammation ➤ Pilot study describes use of prosthetic device for treatment of dry eye ➤ First patient dosed in Phase 3 trial investigating wet AMD treatment ➤ Acquisition and partnership news ➤ ASCRS news and events
With new techniques in (or having recently completed) Phase 3 clinical trials to potentially move crosslinking to the next stage in the U.S., EyeWorld spoke with specialists to look back at where keratoconus monitoring and treatment was, where it is now, and what could be coming.